In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction

Voyager Therapeutics Inc.

www.voyagertherapeutics.com

Latest From Voyager Therapeutics Inc.

Bookmark
  • Analysis

Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech

By Joseph Haas and Jung Won Shin

Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.

Deals Business Strategies
Bookmark
  • News

Voyager Nabs Neurocrine As Partner In CNS Gene Therapy

By Emily Hayes

Voyager signals Phase II study of gene therapy VY-AADC in Parkinson's disease is on track, with no expectations for regulatory setbacks.

Deals Commercial
Bookmark
  • Analysis

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

By Jessica Merrill

Major deal news and exciting science lent boisterous vibe to industry's big meeting. But US drug pricing and macro political issues are factors industry can't ignore – even though it tried to.

Pricing Debate Business Strategies
Bookmark
  • News

J.P. Morgan 2019: Industry Throws A Bonanza, With An Elephant In The Room

By Jessica Merrill

Major deal news and exciting science lent a boisterous vibe to the drug industry's big annual business meeting. But US drug pricing and macro political issues are factors industry can't ignore – even though it tried to.

Business Strategies Leadership
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Voyager Therapeutics Inc.
  • Senior Management
  • Andre Turenne, Pres. & CEO
    Alison Dorval, CFO
    Omar Khwaja, MD, PhD, CMO
    Matthew P Ottmer, COO
    Dinah Sah, PhD, CSO
  • Contact Info
  • Voyager Therapeutics Inc.
    Phone: (857) 259-5340
    75 Sidney St.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By